Anti-CD276 ADC for TNBC Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for triple-negative breast cancer (TNBC) face challenges such as low clinical efficiency and high drug resistance, with limited efficacy of monoclonal antibodies and standard chemotherapies, necessitating the development of targeted therapies that can effectively target and eliminate TNBC cells.
Innovation Solution
An anti-human CD276 monoclonal antibody (mAb) specifically targeting the N-glycosylated extracellular domain of CD276, activating NK/T immune cells and delivering chemotherapy via an antibody-drug conjugate (ADC) to induce direct TNBC cell death and anti-CD276 immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If standard chemotherapies and monoclonal antibodies are used for TNBC treatment, then treatment coverage is broad, but clinical efficiency is low and drug resistance is high
Solution Approach 1:
The patent segments the treatment approach by dividing it into two distinct mechanisms: (1) direct cytotoxic effect through microtubulin polymerization, and (2) immune-mediated effect through CD276 blockade. This segmentation allows each mechanism to address different aspects of tumor elimination, overcoming the limitations of single-mechanism therapies and reducing drug resistance while maintaining broad treatment coverage.
Solution Approach 2:
The patent merges chemotherapy and immunotherapy into a single integrated treatment platform. The anti-CD276 monoclonal antibody is combined with chemotherapeutic agents that target microtubulin, creating a dual-action therapy that simultaneously engages the immune system and directly kills cancer cells, thereby improving clinical efficiency while maintaining versatility across different TNBC cases.
2Reliability
If potent chemotherapeutic drugs are used to achieve direct TNBC cell death, then anti-tumor efficacy is high, but toxicity and side effects increase
Solution Approach 1:
The patent introduces the anti-CD276 monoclonal antibody as an intermediary that mediates tumor cell killing through immune activation. Instead of relying solely on potent chemotherapeutic drugs that directly damage cells (causing high toxicity), the antibody serves as a mediator that recruits and activates immune cells to selectively target and destroy tumor cells, thereby maintaining high anti-tumor efficacy while reducing systemic toxicity and side effects.
3Reliability
If CD276 is targeted to activate NK/T immune cells, then immune response is enhanced, but treatment complexity increases
Solution Approach 1:
The patent employs the self-service principle by designing the anti-CD276 monoclonal antibody to automatically activate NK and T immune cells upon binding to CD276 on tumor cells. The antibody itself serves as the trigger that initiates the immune response without requiring external activation or complex combination regimens. This simplifies the treatment approach while effectively enhancing the immune response against TNBC.
Data Source
AI summary
Disclosed herein is anti-human CD276 mAb expressing the Fc-fused fragments from the extracellular domain of human CD276 (Leu29-Pro245), producing the N-glycosylated peptides as immunogen, and generating hybridoma cells through fusing mouse splenocytes and myeloma cells. The specific targeting of cancer cells and intracellular release of potent drugs enables high anti-cancer efficiency and minimal side effects.